Neurol. praxi. 2011;12(6):407-410

How to reach remission in epilepsy patient

doc.MUDr.Petr Marusič, Ph.D., MUDr.Hana Krijtová
Centrum pro epilepsie, Neurologická klinika 2. LF UK a FN Motol, Praha

Seizure freedom is one of the main goals of therapy in epilepsy patients as it is associated with significant quality of life improvement.

There is still no consensual definition of seizure remission regarding the period of its duration. For patients, long-life remission is definitely

the most acceptable. The way how to reach seizure freedom starts with initial monotherapy with adequately chosen antiepileptic drug.

Most of the patients but not all are responding to moderate or even modest dosing, in some higher or maximal dosing is necessary to

reach the full benefit. In initial monotherapy failure the further step is alternative monotherapy or polytherapy. Though monotherapy

is tradionally viewed as a gold standard, both approaches should be considered in individual patient. In certain cases adding another

drug may be less risky than the trial of converting from one monotherapy to another, mainly in patients with frequent or severe seizures.

Monitoring and assessment of adverse effects of therapy is an inevitable part of epilepsy treatment as these can strongly influence the

quality of life. Polytherapy seems to carry a higher risk of adverse effects however with new mechanism of action of modern drugs and

with individual tailoring of drug dosing the adverse effects are comparable to monotherapy.

Keywords: epilepsy, remission, monotherapy, polytherapy

Published: December 1, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Marusič P, Krijtová H. How to reach remission in epilepsy patient. Neurol. praxi. 2011;12(6):407-410.
Download citation

References

  1. Brázdil M, Hadač J. Definice farmakorezistentní epilepsie, příčiny intraktability. In: Brázdil M, Hadač J, Marusič P (eds.). Farmakorezistentní epilepsie. Triton, Praha 2011; 11-22.
  2. Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta L, Malerba A, Muscas G, La Neve A, Striano P, Perucca E. SOPHIE Study Group. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia 2010; 51(5): 797-804. Go to original source... Go to PubMed...
  3. French JA, Faught E. Rational polytherapy. Epilepsia 2009; 50(Suppl 8): 63-8. Go to original source... Go to PubMed...
  4. Hanna NJ, Black M, Sander JWS, Smithson WH, Appleton R, Brown S, Fish DR (2002). The National Sentinel Clinical Audit of Epilepsy-Related Death: Epilepsy-death in the shadows. The Stationery Office.
  5. Kwan P, Brodie MJ. Effectiveness of first antiepileptic drug. Epilepsia 2001; 42(10): 1255-1260. Go to original source... Go to PubMed...
  6. Sillanpää M, Schmidt D. Natural history of treated childhood-onset epilepsy: prospective, long-term population-based study. Brain. 2006; 129(Pt 3): 617-624. Go to original source... Go to PubMed...
  7. Soubor minimálních diagnostických a terapeutických standardů u pacientů s epilepsií. EpiStop 2010.
  8. Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol 2008; 7(11): 1021-31. Go to original source... Go to PubMed...
  9. Wiebe S, Blume WT, Girvin JP, Eliasziw M. Effectiveness and Efficiency of Surgery for Temporal Lobe Epilepsy Study Group. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N Engl J Med 2001; 345(5): 311-318. Go to original source... Go to PubMed...




Neurology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.